The purpose of this clinical trial is to study the safety and potential benefits of treating fibrotic hypersensitivity pneumonitis (FHP) with an investigational medication. A type of interstitial lung disease (ILD), FHP is scarring of lung tissue from inhaling antigens such as molds, chemicals or dust. This scarring prevents the lungs from moving oxygen from the blood stream to other organs.
Currently, more than 1,400 subjects have been treated with this investigational medication in clinical trials. It has been approved by the Food and Drug Administration (FDA) for use in treating idiopathic pulmonary fibrosis, a different type of ILD, but special permission is required to use it to treat FHP. Some study participants will be given the investigational medication and others will receive a placebo.